Agenus Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Garo H. Armen
- Full Time Employees
- 81
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3 Forbes Road Lexington MA United States of America 02421-7305
- IPO Date
- Feb 8, 2000
- CIK
- 0001098972
- Website
- agenusbio.com
- Similar Companies
- Business
- Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company founded in 1994 and headquartered in Lexington, Massachusetts, discovers, manufactures, and develops therapies that activate the immune system against cancer and infectious diseases. The company focuses on immune checkpoint modulating antibodies including botensilimab, a next-generation CTLA-4 antibody with enhanced Fc functionality, balstilimab, a PD-1 inhibitor, zalifrelimab, a CTLA-4 antibody, and earlier-stage candidates such as AGEN1571 (anti-ILT2), AGEN1777 (TIGIT bispecific), AGEN2373 (CD137), and AGEN1423 (CD73-TGFβ); adoptive cell therapies through its subsidiary MiNK Therapeutics, Inc. (Nasdaq: INKT); and vaccine adjuvants via SaponiQx, Inc., featuring proprietary QS-21 from cultured plant cells and platforms like Retrocyte Display for antibody discovery and AdenoJuice for personalized vaccines. Agenus operates primarily in the United States and Europe, with a pipeline targeting solid tumors such as metastatic colorectal cancer, cervical cancer, and other treatment-resistant malignancies, supported by in-house cGMP manufacturing capabilities. In recent developments, Agenus entered a $141 million strategic collaboration with Zydus Lifesciences in June 2025, exchanging its biologics CMC facilities in Emeryville and Berkeley, California, for $75 million upfront plus up to $50 million in contingent payments, alongside a $16 million equity investment from Zydus and an exclusive manufacturing agreement for botensilimab/balstilimab (BOT/BAL) to support clinical and commercial scale-up. Earlier, in May 2024, the company secured a $100 million royalty financing agreement with Ligand Pharmaceuticals, with potential syndication up to $200 million, to fund BOT/BAL's Phase 3 trial in relapsed/refractory microsatellite stable colorectal cancer and launch activities. Additional advancements include completing enrollment in a Phase 2 BOT/BAL trial in advanced MSS colorectal cancer, receiving Fast Track Designation, launching a Q4 2025 international trial across Canada, France, Australia, and New Zealand, and appointing Dr. José Iglesias as Chief Medical Affairs Officer to expand global access programs.
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript
Agenus shares surge as company secures up to $340M to advance colon cancer trial
Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing
Agenus shares surge as company secures up to $340M to advance colon cancer trial
VivoPower earns Outperform rating as Noble bets on "power-first" AI strategy
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
AGEN Early Access Revenues Signal a New Path Ahead of Approval
Is Agenus Stock a Hold Amid Valuation and Funding Risks?
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC
Agenus Announces Virtual 2026 Annual Shareholders Meeting
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?